Marizomib for central nervous system-multiple myeloma. Br J Haematol 2017 Apr;177(2):221-225
Date
04/08/2017Pubmed ID
28387460DOI
10.1111/bjh.14498Scopus ID
2-s2.0-85017133877 (requires institutional sign-in at Scopus site) 48 CitationsAbstract
Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifestation of extra-medullary disease with few therapeutic options, highlighting the unmet clinical need in these patients. Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. Herein, we present two patients with RRMM and CNS involvement who benefited from marizomib-based therapy. These cases provide the first proof of principle for further exploring marizomib in CNS-MM patients.
Author List
Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari PAuthors
Binod Dhakal MD Associate Professor in the Medicine department at Medical College of WisconsinParameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultCentral Nervous System Neoplasms
Humans
Lactones
Male
Middle Aged
Multiple Myeloma
Pyrroles
